[1]Anger H O, Gottschalk A. Localization of brain tumors with the positron scintillation camera[J]. J Nucl Med, 1963, 4: 326-330.
[2]Greene M W, Tucker W D. An improved gallium-68 cow[J]. The International Journal of Applied Radiation and Isotopes, 1961, 12(1-2): 62-63.
[3]Loc’h C, Maziere B, Comar D. A new generator for ionic gallium-68[J]. J Nucl Med, 1980, 21(2): 171-173.
[4]Rosch F. Past, present and future of 68Ge/68Ga generators[J]. Appl Radiat Isot, 2013, 76: 24-30.
[5]Chakravarty R, Chakraborty S, Ram R, et al. Detailed evaluation of different 68Ge:68Ga generators an attempt toward achieving efficient 68Ga radiopharmacy[J]. J Label Compd Radiopharm, 2016, 59: 87-94.
[6]Sudbrock F, Fischer T, Zimmermanns B, et al. Characterization of SnO2-based 68Ge: 68Ga generators and 68Ga-DOTATATE preparations radionuclide purity, radiochemical yield and long-term constancy[J]. EJNMMI Research, 2014, 4(1): 36.
[7]De Blois E, Sze Chan H, Naidoo C, et al. Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides[J]. Appl Radiat Isot, 2011, 69(2): 308-315.
[8]Velikyan I. 68Ga-Based radiopharmaceuticals: production and application relationship[J]. Molecules, 2015, 20(7): 12913-12943.
[9]Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?[J]. Eur J Nucl Med Mol Imaging, 2007, 34(7): 982-893.
[10]Velikyan I, Beyer G J, Långström B. Microwave-supported preparation of 68Ga-bioconjugates with high specific radioactivity[J]. Bioconjugate Chem, 2004, (15): 554-560.
[11]Velikyan I, Xu H, Nair M, et al. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE[J]. Nucl Med Biol, 2012, 39(5): 628-639. |